Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
EGLT's Cash to Debt is ranked higher than
79% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. EGLT: No Debt )
EGLT' s 10-Year Cash to Debt Range
Min: 0.18   Max: No Debt
Current: No Debt

Equity to Asset 0.73
EGLT's Equity to Asset is ranked higher than
76% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EGLT: 0.73 )
EGLT' s 10-Year Equity to Asset Range
Min: -3.39   Max: 0.73
Current: 0.73

-3.39
0.73
Z-Score: 3.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1936.34
EGLT's Operating margin (%) is ranked higher than
54% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. EGLT: -1936.34 )
EGLT' s 10-Year Operating margin (%) Range
Min: -1934.17   Max: -440.97
Current: -1936.34

-1934.17
-440.97
Net-margin (%) -2253.28
EGLT's Net-margin (%) is ranked higher than
53% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. EGLT: -2253.28 )
EGLT' s 10-Year Net-margin (%) Range
Min: -2250.73   Max: -449.46
Current: -2253.28

-2250.73
-449.46
ROE (%) -107.07
EGLT's ROE (%) is ranked higher than
55% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. EGLT: -107.07 )
EGLT' s 10-Year ROE (%) Range
Min: -444.79   Max: -444.79
Current: -107.07

ROA (%) -71.29
EGLT's ROA (%) is ranked higher than
56% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. EGLT: -71.29 )
EGLT' s 10-Year ROA (%) Range
Min: -155.7   Max: -106.79
Current: -71.29

-155.7
-106.79
ROC (Joel Greenblatt) (%) -1327.06
EGLT's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. EGLT: -1327.06 )
EGLT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1137.7   Max: -687.52
Current: -1327.06

-1137.7
-687.52
» EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

EGLT Guru Trades in

EGLT Guru Trades in

EGLT Guru Trades in

Q1 2014

EGLT Guru Trades in Q1 2014

Steven Cohen 31,594 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.80
EGLT's P/B is ranked higher than
73% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. EGLT: 3.80 )
EGLT' s 10-Year P/B Range
Min: 1.41   Max: 6.22
Current: 3.8

1.41
6.22
P/S 73.24
EGLT's P/S is ranked lower than
53% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. EGLT: 73.24 )
EGLT' s 10-Year P/S Range
Min: 37.92   Max: 603
Current: 73.24

37.92
603
EV-to-EBIT -2.99
EGLT's EV-to-EBIT is ranked lower than
53% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EGLT: -2.99 )
EGLT' s 10-Year EV-to-EBIT Range
Min: -6.7   Max: -0.3
Current: -2.99

-6.7
-0.3
Current Ratio 7.42
EGLT's Current Ratio is ranked higher than
83% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. EGLT: 7.42 )
EGLT' s 10-Year Current Ratio Range
Min: 0.17   Max: 7.42
Current: 7.42

0.17
7.42
Quick Ratio 7.42
EGLT's Quick Ratio is ranked higher than
83% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. EGLT: 7.42 )
EGLT' s 10-Year Quick Ratio Range
Min: 0.17   Max: 7.42
Current: 7.42

0.17
7.42
Days Sales Outstanding 321.61
EGLT's Days Sales Outstanding is ranked higher than
67% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. EGLT: 321.61 )
EGLT' s 10-Year Days Sales Outstanding Range
Min: 56.56   Max: 321.28
Current: 321.61

56.56
321.28

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.60
EGLT's Price/Net Cash is ranked higher than
89% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. EGLT: 4.60 )
EGLT' s 10-Year Price/Net Cash Range
Min: 2.7   Max: 2.7
Current: 4.6

Price/Net Current Asset Value 4.40
EGLT's Price/Net Current Asset Value is ranked higher than
88% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. EGLT: 4.40 )
EGLT' s 10-Year Price/Net Current Asset Value Range
Min: 2.53   Max: 2.53
Current: 4.4

Price/Tangible Book 3.80
EGLT's Price/Tangible Book is ranked higher than
80% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. EGLT: 3.80 )
EGLT' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 3.71
Current: 3.8

1.9
3.71
Price/Median PS Value 0.60
EGLT's Price/Median PS Value is ranked higher than
94% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. EGLT: 0.60 )
EGLT' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 0.37
Current: 0.6

Earnings Yield (Greenblatt) -33.10
EGLT's Earnings Yield (Greenblatt) is ranked lower than
60% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. EGLT: -33.10 )
EGLT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -38   Max: 0
Current: -33.1

-38
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for EGLT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest percentage decreases Apr 29 2015
PhRMA Names Horizon Pharma plc Chairman and CEO Timothy P. Walbert to Board of Directors Apr 28 2015
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2015 Financial Results on May 7,... Apr 23 2015
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2015 Financial Results on May 7,... Apr 23 2015
EGALET CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Apr 14 2015
Egalet Appoints Nicholas Nicolaides, Ph.D. and John Osborn to Board of Directors Apr 13 2015
Egalet Appoints Nicholas Nicolaides, Ph.D. and John Osborn to Board of Directors Apr 13 2015
EGALET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Apr 08 2015
Egalet Announces Closing of $60 Million Offering of Convertible Senior Notes Due 2020 Apr 07 2015
Egalet Announces Closing of $60 Million Offering of Convertible Senior Notes Due 2020 Apr 07 2015
EGALET CORP Files SEC form 8-K, Other Events Apr 06 2015
EGALET CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Apr 02 2015
Egalet (EGLT) in Focus: Stock Plunges 11.5% - Tale of the Tape Apr 02 2015
Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 Apr 01 2015
/C O R R E C T I O N -- Egalet Corporation/ Apr 01 2015
Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 Apr 01 2015
EGALET CORP Files SEC form 8-K/A, Financial Statements and Exhibits Mar 25 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 25 2015
Egalet to hire up to 60 sales reps for launch of two pain medicines Mar 25 2015
Egalet Provides Commercial Update on SPRIX® and OXAYDO™ Mar 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK